Amicus Therapeutics (FOLD) Set to Announce Earnings on Thursday

Amicus Therapeutics (NASDAQ:FOLD) will announce its earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of $0.03 per share for the quarter. Amicus Therapeutics has set its FY 2024 guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.04. Amicus Therapeutics had a negative net margin of 34.73% and a negative return on equity of 77.08%. The business had revenue of $110.40 million during the quarter, compared to analysts’ expectations of $111.19 million. During the same quarter last year, the company earned ($0.18) earnings per share. The firm’s revenue was up 27.9% on a year-over-year basis. On average, analysts expect Amicus Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amicus Therapeutics Stock Performance

FOLD traded up $0.30 on Tuesday, hitting $9.85. 1,285,853 shares of the stock traded hands, compared to its average volume of 2,815,126. The business has a fifty day moving average price of $10.12 and a two-hundred day moving average price of $11.11. The company has a current ratio of 3.03, a quick ratio of 2.61 and a debt-to-equity ratio of 2.97. The firm has a market capitalization of $2.92 billion, a PE ratio of -19.49 and a beta of 0.71. Amicus Therapeutics has a 52 week low of $9.02 and a 52 week high of $14.57.

Insider Activity at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $10.34, for a total value of $77,550.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $9,168,002.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 6,100 shares of the firm’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $10.00, for a total transaction of $61,000.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,866,540. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $10.34, for a total transaction of $77,550.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,168,002.36. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on FOLD. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research note on Friday, May 10th. Morgan Stanley lowered their price target on shares of Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Friday, May 10th. Wells Fargo & Company initiated coverage on shares of Amicus Therapeutics in a research report on Thursday, May 30th. They set an “overweight” rating and a $18.00 target price on the stock. Guggenheim raised shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Tuesday, May 14th. Finally, Bank of America cut their price target on shares of Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $17.57.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.